ARCHIVES

Phase III Ramucirumab Trial Fails Primary Endpoint of PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Sends A Second Letter To Groups About Carboplatin

October 22, 2010

NCI Agrees To give NSABP One Year Until Competition; Advisors OK Concept

June 17, 1994

Facility Needs Panel Recommends $4.5-3 billion, Seven Year Program To Be Run By NIGMS Or DRR

March 4, 1988

FCRF Contracts Recompetition Will Be Along Same Lines As in 1982 But for at Least Seven Years

July 5, 1985

Cancer Cases To Double By 2050 As U.S. Population Ages, Annual Report Says.

May 17, 2002

Clinical Trials Approved By NCI CTEP Last Month

January 28, 2011